CKPT Quote, Financials, Valuation and Earnings

Fortress Biotech has a net margin of -16268.29% compared to Checkpoint Therapeutics's net margin of -87.96%. Checkpoint Therapeutics's return on equity of -- beat Fortress Biotech's return on equity of --.

Checkpoint Therapeutics has a consensus price target of $4.33, signalling upside risk potential of 8.61%. On the other hand Fortress Biotech has an analysts' consensus of $15.33 which suggests that it could grow by 950.23%. Given that Fortress Biotech has higher upside potential than Checkpoint Therapeutics, analysts believe Fortress Biotech is more attractive than Checkpoint Therapeutics.

Checkpoint Therapeutics has a beta of 1.211, which suggesting that the stock is 21.135% more volatile than S&P 500. In comparison Fortress Biotech has a beta of 1.825, suggesting its more volatile than the S&P 500 by 82.547%.

Checkpoint Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Checkpoint Therapeutics pays -- of its earnings as a dividend. Fortress Biotech pays out -10.24% of its earnings as a dividend.

Checkpoint Therapeutics quarterly revenues are $41K, which are smaller than Fortress Biotech quarterly revenues of $14.6M. Checkpoint Therapeutics's net income of -$9.7M is higher than Fortress Biotech's net income of -$12.9M. Notably, Checkpoint Therapeutics's price-to-earnings ratio is -- while Fortress Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Checkpoint Therapeutics is -- versus 0.41x for Fortress Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Protagonist Therapeutics has a net margin of -16268.29% compared to Checkpoint Therapeutics's net margin of 77.17%. Checkpoint Therapeutics's return on equity of -- beat Protagonist Therapeutics's return on equity of 52.01%.

Checkpoint Therapeutics has a consensus price target of $4.33, signalling upside risk potential of 8.61%. On the other hand Protagonist Therapeutics has an analysts' consensus of $69.10 which suggests that it could grow by 62.13%. Given that Protagonist Therapeutics has higher upside potential than Checkpoint Therapeutics, analysts believe Protagonist Therapeutics is more attractive than Checkpoint Therapeutics.

Checkpoint Therapeutics has a beta of 1.211, which suggesting that the stock is 21.135% more volatile than S&P 500. In comparison Protagonist Therapeutics has a beta of 2.305, suggesting its more volatile than the S&P 500 by 130.476%.

Checkpoint Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protagonist Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Checkpoint Therapeutics pays -- of its earnings as a dividend. Protagonist Therapeutics pays out -- of its earnings as a dividend.

Checkpoint Therapeutics quarterly revenues are $41K, which are smaller than Protagonist Therapeutics quarterly revenues of $170.6M. Checkpoint Therapeutics's net income of -$9.7M is lower than Protagonist Therapeutics's net income of $131.7M. Notably, Checkpoint Therapeutics's price-to-earnings ratio is -- while Protagonist Therapeutics's PE ratio is 10.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Checkpoint Therapeutics is -- versus 6.21x for Protagonist Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Rigel Pharmaceuticals has a net margin of -16268.29% compared to Checkpoint Therapeutics's net margin of 24.9%. Checkpoint Therapeutics's return on equity of -- beat Rigel Pharmaceuticals's return on equity of --.

Checkpoint Therapeutics has a consensus price target of $4.33, signalling upside risk potential of 8.61%. On the other hand Rigel Pharmaceuticals has an analysts' consensus of $33.67 which suggests that it could grow by 101.84%. Given that Rigel Pharmaceuticals has higher upside potential than Checkpoint Therapeutics, analysts believe Rigel Pharmaceuticals is more attractive than Checkpoint Therapeutics.

Checkpoint Therapeutics has a beta of 1.211, which suggesting that the stock is 21.135% more volatile than S&P 500. In comparison Rigel Pharmaceuticals has a beta of 1.319, suggesting its more volatile than the S&P 500 by 31.928%.

Checkpoint Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Checkpoint Therapeutics pays -- of its earnings as a dividend. Rigel Pharmaceuticals pays out -- of its earnings as a dividend.

Checkpoint Therapeutics quarterly revenues are $41K, which are smaller than Rigel Pharmaceuticals quarterly revenues of $57.6M. Checkpoint Therapeutics's net income of -$9.7M is lower than Rigel Pharmaceuticals's net income of $14.3M. Notably, Checkpoint Therapeutics's price-to-earnings ratio is -- while Rigel Pharmaceuticals's PE ratio is 17.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Checkpoint Therapeutics is -- versus 1.64x for Rigel Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Trevi Therapeutics has a net margin of -16268.29% compared to Checkpoint Therapeutics's net margin of --. Checkpoint Therapeutics's return on equity of -- beat Trevi Therapeutics's return on equity of --.

Checkpoint Therapeutics has a consensus price target of $4.33, signalling upside risk potential of 8.61%. On the other hand Trevi Therapeutics has an analysts' consensus of $19.83 which suggests that it could grow by 256.72%. Given that Trevi Therapeutics has higher upside potential than Checkpoint Therapeutics, analysts believe Trevi Therapeutics is more attractive than Checkpoint Therapeutics.

Checkpoint Therapeutics has a beta of 1.211, which suggesting that the stock is 21.135% more volatile than S&P 500. In comparison Trevi Therapeutics has a beta of 0.406, suggesting its less volatile than the S&P 500 by 59.351%.

Checkpoint Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Trevi Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Checkpoint Therapeutics pays -- of its earnings as a dividend. Trevi Therapeutics pays out -- of its earnings as a dividend.

Checkpoint Therapeutics quarterly revenues are $41K, which are larger than Trevi Therapeutics quarterly revenues of --. Checkpoint Therapeutics's net income of -$9.7M is higher than Trevi Therapeutics's net income of -$11.4M. Notably, Checkpoint Therapeutics's price-to-earnings ratio is -- while Trevi Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Checkpoint Therapeutics is -- versus -- for Trevi Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.